Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Shulman

Showing results (101-110 of 282) with videos related to

Pageof 29
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1994
Improved survival in patients with limited stage IIIA Hodgkin's disease treated with combined radiation therapy and chemotherapyK C Marcus, L A Kalish, C N Coleman, et al.
JCO Oncology Practice|March 12, 2021
Time to Treatment Initiation for Breast Cancer During the 2020 COVID-19 PandemicKathryn Hawrot, Lawrence N Shulman, Ira J Bleiweiss, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2000
Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancerK D Miller, J Picus, C Blanke, et al.
Journal of the American College of Surgeons|December 17, 2016
Reliability of the American College of Surgeons Commission on Cancer's Quality of Care Measures for Hospital and Surgeon ProfilingJason B Liu, Kristopher M Huffman, Bryan E Palis, et al.
JCO Global Oncology|July 12, 2022
Nephroblastoma Treatment and Outcomes in a Low-Income SettingCyprien Shyirambere, Chandler Villaverde, Cam Nguyen, et al.
Cancer Chemotherapy and Pharmacology|January 5, 2002
Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignanciesC A Bunnell, J G Supko, J P Eder, et al.
Surgical Oncology|June 2, 2021
Risk factors for the presence of residual disease in women after partial mastectomy for invasive breast cancer: A single institution experienceLauren M DeStefano, Lauren Coffua, Elise Wilson, et al.
Breast Cancer Research and Treatment|May 24, 2019
Does time to adjuvant chemotherapy (TTC) affect outcomes in patients with triple-negative breast cancer?Maria K Pomponio, Luke J Keele, Kevin R Fox, et al.
The Lancet. Oncology|August 20, 2021
The impact of scaling up access to treatment and imaging modalities on global disparities in breast cancer survival: a simulation-based analysisZachary J Ward, Rifat Atun, Hedvig Hricak, et al.
Journal of Global Oncology|July 19, 2017
Treatment of Chronic Myeloid Leukemia in Rural Rwanda: Promising Early OutcomesNeo Tapela, Ignace Nzayisenga, Roshan Sethi, et al.
Pageof 29

Showing results (101-110 of 282) with videos related to

Sort By:
Pageof 29
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1994
Improved survival in patients with limited stage IIIA Hodgkin's disease treated with combined radiation therapy and chemotherapyK C Marcus, L A Kalish, C N Coleman, et al.
JCO Oncology Practice|March 12, 2021
Time to Treatment Initiation for Breast Cancer During the 2020 COVID-19 PandemicKathryn Hawrot, Lawrence N Shulman, Ira J Bleiweiss, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2000
Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancerK D Miller, J Picus, C Blanke, et al.
Journal of the American College of Surgeons|December 17, 2016
Reliability of the American College of Surgeons Commission on Cancer's Quality of Care Measures for Hospital and Surgeon ProfilingJason B Liu, Kristopher M Huffman, Bryan E Palis, et al.
JCO Global Oncology|July 12, 2022
Nephroblastoma Treatment and Outcomes in a Low-Income SettingCyprien Shyirambere, Chandler Villaverde, Cam Nguyen, et al.
Cancer Chemotherapy and Pharmacology|January 5, 2002
Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignanciesC A Bunnell, J G Supko, J P Eder, et al.
Surgical Oncology|June 2, 2021
Risk factors for the presence of residual disease in women after partial mastectomy for invasive breast cancer: A single institution experienceLauren M DeStefano, Lauren Coffua, Elise Wilson, et al.
Breast Cancer Research and Treatment|May 24, 2019
Does time to adjuvant chemotherapy (TTC) affect outcomes in patients with triple-negative breast cancer?Maria K Pomponio, Luke J Keele, Kevin R Fox, et al.
The Lancet. Oncology|August 20, 2021
The impact of scaling up access to treatment and imaging modalities on global disparities in breast cancer survival: a simulation-based analysisZachary J Ward, Rifat Atun, Hedvig Hricak, et al.
Journal of Global Oncology|July 19, 2017
Treatment of Chronic Myeloid Leukemia in Rural Rwanda: Promising Early OutcomesNeo Tapela, Ignace Nzayisenga, Roshan Sethi, et al.
Pageof 29